Publications by authors named "Oscar Nantes"
Article Synopsis
- The study aimed to evaluate the effects of switching from the adalimumab (ADA) originator to its biosimilars on treatment persistence, clinical efficacy, and safety in patients with inflammatory bowel disease.
- A total of 524 patients were analyzed, with some maintaining the ADA originator and others switching to biosimilars, showing similar rates of treatment discontinuation and relapse between the two groups.
- The findings concluded that switching to ADA biosimilars did not negatively impact patient outcomes compared to continuing with the ADA originator.
Background: Capsule endoscopy (SBCE) has developed a relevant role in patients with established Crohn's Disease (CD). However, evaluation of the impact in clinical management has been scarce.
Aims: To evaluate therapeutic impact of SBCE in an 11-year real-life cohort of known CD patients.
Article Synopsis
- A study was conducted to evaluate the long-term effects of stopping anti-TNF treatment in patients with inflammatory bowel disease (IBD), focusing on relapse rates after discontinuation during clinical remission.
- The study involved 1,055 patients and revealed a 12% yearly relapse rate, with 50% experiencing a relapse within five years, while many managed to regain remission after retreatment or switching therapies.
- Overall, the findings suggest that while many patients remain in remission post-discontinuation, retreatment with the same anti-TNF is often effective for those who relapse, and alternative therapies can also lead to remission in non-responders.
Introduction: Knowing the natural history of ulcerative colitis (UC) is essential to understand the course of the disease, assess the impact of different treatment strategies and identify poor prognostic factors. One of the most significant matters in this regard is the need for surgery.
Objectives: To analyse the Colectomy Incidence Rate (CIR) from diagnosis to end of follow-up (31/12/2017) and identify predictive factors for colectomy.
Article Synopsis
- Tacrolimus is a medicine used to help prevent organ rejection in transplant patients and may also help people with inflammatory bowel disease (IBD).
- A study in Spain looked at 143 adult patients with IBD who took tacrolimus for 3 months, and many showed improvement in their symptoms.
- Some patients had side effects, and 84% stopped taking the medicine because it stopped working for them, with a small number developing serious issues like cancer.
To evaluate outcomes of early dose optimization of golimumab in ulcerative colitis (UC) patients with inadequate response to golimumab induction treatment. This observational, multicenter, cohort study included patients with moderate-to-severe active UC and with inadequate response to subcutaneous golimumab induction doses, in whom weight-based golimumab maintenance dose (European labeling) of 50 mg every 4 weeks (q4wk) was optimized before week 14 to 100 mg q4wk. At week 14, we assessed clinical response and remission using the partial Mayo score.
View Article and Find Full Text PDFAim: To assess the likelihood of detecting latent tuberculosis infection [LTBI] by the positive conversion of a serial tuberculin skin test [TST] at 1 year in inflammatory bowel disease [IBD] patients with negative baseline two-step TST.
Methods: In this multicentre prospective cohort study, we evaluated rate and predictors of conversion of TST at 1 year in patients with negative baseline TST. We also evaluated management of patients who had a positive TST at baseline or a conversion at 1 year.
Background: Adalimumab is the second tumour necrosis factor antagonist (anti-TNF) adopted for the treatment of ulcerative colitis. Clinical data from naïve patients are scarce.
Aim: Examine the response to adalimumab in TNF-antagonist-naïve patients.
Background And Aims: Inflammatory bowel disease is a chronic disorder of the gastrointestinal tract. Tacrolimus is a calcineurin inhibitor used in the prophylaxis of rejection after a solid organ transplant. There is some evidence for its use in inflammatory bowel disease, although there is a lack of information about the patients who will benefit the most with this drug and the prognostic factors for a favorable response.
View Article and Find Full Text PDFBackground: The "Adult Eosinophilic Esophagitis Quality of Life (EoE-QoL-A) Questionnaire" was developed in English as a valid, reliable, and disease-specific health-related QoL measure.This research aims to adapt and validate this questionnaire for Spanish-speaking patients.
Patients And Methods: A multicenter, observational, prospective study was conducted at 8 Spanish hospitals.
Unlabelled: In the last few years, the number of anticoagulated patients has significantly increased and, as a consequence, so have hemorrhagic complications due to this therapy. We analyzed gastrointestinal (GI) bleeding because it is the most frequent type of major bleeding in these patients, and we hypothesized that they would have lesions responsible for GI bleeding regardless of the intensity of anticoagulation, although excessively anticoagulated patients would have more serious hemorrhages.
Objectives: To study the characteristics of anticoagulated patients with GI bleeding and the relationship between the degree of anticoagulation and a finding of causative lesions and bleeding severity.
Background: Eosinophilic oesophagitis has emerged as a common cause of oesophageal symptoms.
Aims: To document practice variation in care provided to eosinophilic oesophagitis patients in Spain and to assess adherence to available guidelines.
Methods: A prospective survey-based registry including data from all patients receiving care from gastroenterologists and allergists throughout Spain was developed.